title: Allergic rhinitis: an update on disease, present treatments and future prospects.
abstract: Allergic rhinitis (AR) is an inflammation of nasal mucosa mediated by IgE-associated processes occurring independently, or concurrently with asthma. AR is characterized by sensitization-formation and expression of antigen specific IgE, followed by inflammation in two phases. The early phase response involves cross linking of IgE molecules leading to degranulation of mast cells and release of preformed mediators such as histamine and tryptase, or newly synthesized mediators such as prostaglandins and leukotrienes. The late phase response is predominated by the presence of eosinophils, lymphocytes, cytokines, and adhesion molecules. Newer insights reveal that the whole phenomenon of immunological inflammation is intricately knit with neural pathways, which strongly influence the process. Furthermore, AR can impact psychological health and vice versa. Classical pharmacotherapy of AR includes use of oral or topical antihistamines, oral antileukotrienes, topical corticosteroids, mast cell stabilizers, decongestants, and an anticholinergic agent. Among immunomodulatory treatments, immunotherapy is gaining widespread use, while antibody treatment is restricted mainly to resistant cases. Several small molecules with improved safety profile, or targeting novel mechanisms are in the clinical research. Newer antihistamines and corticosteroids with improved safety profile and antagonists of the prostaglandin D(2) (CRTH2) receptors are likely to be available for clinical use in the near future. Lack of properly validated animal models and complexities associated with clinical evaluation are some of the challenges facing the researchers in AR. Comprehensive understanding of immunological and neurological processes in AR would facilitate the future quest for more effective and safer management of this disease.
authors.affiliation: Pharmacology Division, Sun Pharma Advanced Research Company Limited, Atladara, Tandalja Road, Vadodara, Gujarat 390 020, India. sanjay.mandhane@sunpharma.com
authors.forename: Sanjay N
authors.initials: SN
authors.lastname: Mandhane
authors.forename: Jigar H
authors.initials: JH
authors.lastname: Shah
authors.forename: Rajamannar
authors.initials: R
authors.lastname: Thennati
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000150:complications / Q000453:epidemiology; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D006633:Histamine Antagonists; D020024:Leukotriene Antagonists